Dehydroaglaiastatin is primarily investigated for its potent biological activity, especially in the field of cancer research. It exhibits strong antiproliferative effects against various cancer cell lines by inhibiting key cellular processes involved in tumor growth. The compound functions as a microtubule-targeting agent, disrupting mitotic spindle formation during cell division, which leads to cell cycle arrest and apoptosis in malignant cells.

Due to its unique structural features and mechanism of action, dehydroaglaiastatin serves as a valuable lead compound in the development of novel chemotherapeutic agents. It shows promise in overcoming drug resistance observed with other microtubule inhibitors, making it a focus in the design of next-generation anticancer drugs. Research is ongoing to optimize its delivery and reduce toxicity while maintaining high potency.